This press release shall not constitute an offer to sell or a solicitation of an offer to buy, nor shall there be any sale of ...

PRINCETON - PDS Biotechnology Corporation (NASDAQ:PDSB) has confirmed plans to commence its VERSATILE-003 Phase 3 clinical trial for a promising cancer immunotherapy within the first quarter of 2025.

Amid the federal funding uncertainty for health and sciences, local life science leaders say this could be a moment for industry partners, investors and others to step up and support the sector.

MALVERN, Pa. - Annovis Bio Inc. (NYSE: ANVS), a clinical-stage drug platform company trading near its 52-week low of $2.99, has announced the initiation of a Phase 3 trial for its Alzheimer's disease ...

A research team from POSTECH has developed a biodegradable polymer-based delivery system that efficiently transports mRNA.

New research from the University of Illinois shows that gene-edited bacteria can supply early corn plants the equivalent of 35 pounds of nitrogen from the air. Study co-author Connor Sible, research ...